Norges Bank Tcr2 Therapeutics Inc. Transaction History

Norges Bank

  • $716 Trillion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2019

Aug 09, 2019
SELL
$13.64 - $20.97 $341,000 - $524,250
-25,000 Closed
0 $0
Q1 2019

May 11, 2020
BUY
$15.01 - $22.15 $375,250 - $553,750
25,000 New
25,000 $436,000

About TCR2 THERAPEUTICS INC.

TCRR Quotes by TradingView
  • Ticker TCRR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,606,400
  • Description
  • TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...
More about TCRR
Track This Portfolio

Track Norges Bank Portfolio

Follow Norges Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

News

Stay updated on Norges Bank with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email